Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867770 | 1.00 | DAO (0.35) | DAO | |
| SCHEMBL31489236 | 0.83 | DAO (0.32) | DAO | |
| SCHEMBL9939110 | 0.77 | DAO (0.37) | DAO | |
| SCHEMBL31440837 | 0.77 | DAO (0.37) | DAO | |
| SCHEMBL26615878 | 0.77 | DAO (0.37) | DAO | |
| SCHEMBL16976166 | 0.77 | CCR1 (0.38) | — | |
| SCHEMBL30631397 | 0.77 | CCR1 (0.38) | — | |
| SCHEMBL28718640 | 0.75 | — | — | |
| SCHEMBL29559895 | 0.75 | — | — | |
| SCHEMBL25348733 | 0.74 | PDXK (0.34) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598915-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076670-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| WO-2013051639-A1 | PYRAZOLOQUINOLINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | DAO 3839/4885 |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | DAO 1598/4885 |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | DAO 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.